2009
DOI: 10.1590/s0102-311x2009001000017
|View full text |Cite
|
Sign up to set email alerts
|

Antiretroviral manufacturers and the challenge of universal access to drugs through the Brazilian National STD/AIDS Program

Abstract: This article describes the antiretroviral (ARV) manufacturing market in

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0
1

Year Published

2012
2012
2022
2022

Publication Types

Select...
3
1
1

Relationship

1
4

Authors

Journals

citations
Cited by 10 publications
(3 citation statements)
references
References 9 publications
0
2
0
1
Order By: Relevance
“…By late 1990s, the author showed that the lack of investment in the first and second stages by companies, and the international recognition of patent laws, placed developing countries, including Brazil, in a situation of critical dependence on exogenous technological transfer 24 . In less than a decade, the technological leadership of Farmanguinhos was challenged by the entrance of new drugs for Aids treatment, protected by the new patent regime and imported medicine 23 .…”
Section: Farmanguinhos and Pdpmentioning
confidence: 99%
“…By late 1990s, the author showed that the lack of investment in the first and second stages by companies, and the international recognition of patent laws, placed developing countries, including Brazil, in a situation of critical dependence on exogenous technological transfer 24 . In less than a decade, the technological leadership of Farmanguinhos was challenged by the entrance of new drugs for Aids treatment, protected by the new patent regime and imported medicine 23 .…”
Section: Farmanguinhos and Pdpmentioning
confidence: 99%
“…In Brazil, the governmental AIDS program provides universal access to diagnosis, therapy and routine laboratory tests (including CD4 lymphocytes count, measures of viral load and genotyping of viral resistance) [7]. This approach reduced mortality and slowed the growth of the epidemics [8], [9].…”
Section: Introductionmentioning
confidence: 99%
“…adoecimento (NYIRENDA et al, 2012;LINLEY et al, 2012;BROOKS et al, 2012;HENRY, 2009;MAYER et al, 2012;ADANS et al, 2011;CAMARGO et al, 2012;TAQUETTE et al, 2011;TAQUETTE 2013;VERAS et al 2011;MELENDEZ et al, 2009, LOPES et al, 2011GASPAR et al, 2011); prevenção em HIV/aids: estratégias dos serviços e conhecimento social (FERRAZ et al, 2009;ZAMBENEDETTI, 2012;FARR et al, 2009;TITUS et al, 2009;KENNY et al, 2012;DAVIS et al, 2012;MOURA et al, 2013;TORRES et al, 2011;MONFORTE et al, 2013); impacto das políticas de combate ao HIV/aids no Brasil e no mundo (GRANGEIRO et al, 2009b;HORWOOD et al, 2010;NYIRENDA et al, 2012;FERRAZ et al, 2009;JOHNSON et al, 2013;KUROKAWA et al, 2013;ZAMBENEDETTI, 2012;ZHOU et al, 2011); avaliação da assistência às PVHAorganização dos serviços, acesso à TARV e adesão ao tratamento (NEMES et al, 2013;SILVA et al, 2009;LAGO et al, 2009;FERNANDES et al, 2009;NEMES et al, 2009;CARACIOLO et al, 2009;ZAMBENEDETTI et al, 2013;BARBOSA et al, 2009;OLIVEIRA, 2009;REGO et al, 2010); e desafio...…”
Section: Diferentes Perfis De Vulnerabilidade Individual E Social Relunclassified